Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review
- 12 January 2017
- journal article
- review article
- Published by Springer Nature in International Urogynecology Journal
- Vol. 28 (6) , 805-816
Abstract
Introduction and hypothesis Patients with refractory overactive bladder (OAB) pose a therapeutic challenge. Guidelines such as those from the National Institute for Health and Care Excellence recommend invasive treatments such as botulinum toxin-A ((BTX-A), sacral neural stimulation (SNS) etc. only if there is detrusor overactivity (DO) on urodynamics. Methods Our aim was to systematically evaluate evidence based on the presence or absence of DO in relation to differences in effectiveness and complications related to invasive treatment in patients with refractory OAB. We carried out a systematic search of Cochrane, MEDLINE, Embase, CINAHL, LILACS, meta-Register of Controlled Trials (mRCT), CENTRAL, and Google Scholar databases from inception until April 2016. Abstracts presented at IUGA, ICS and EAU conferences (until April 2016) were included and journals that were hand searched. Results We found five studies (two prospective cohort studies and subgroup analyses of two randomized controlled trials (RCTs) and one cohort study for BTX-A, one multicenter prospective cohort study for percutaneous tibial nerve stimulation (PTNS) and three (one RCT and two cohort studies) for SNS. The outcomes in patients without (n = 77) or with (n = 135) DO were similar in the context of urodynamic findings, bladder diaries, quality of life (QoL) questionnaires, etc. when treated with BTX-A [odds ratio (OR) 1.52, 95% confidence interval (CI) 0.40–5.77] or SNS (50 patients without and 81 with DO; OR1.37, CI 0.76–2.48). Outcomes for PTNS (based on a single study) seem to be better in patients without DO. Conclusion The limited evidence suggests that urodynamic diagnosis of DO does not alter patient reported outcomes for invasive treatments such as BTX-A and SNS. Noninferiority RCTs powered to evaluate the role of DO in predicting treatment response are required.Keywords
This publication has 25 references indexed in Scilit:
- How to Use a Subgroup AnalysisJAMA, 2014
- OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2013
- Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta‐analysisNeurourology and Urodynamics, 2012
- An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunctionInternational Urogynecology Journal, 2009
- Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor OveractivityEuropean Urology, 2006
- CHANGES IN BRAIN ACTIVITY FOLLOWING SACRAL NEUROMODULATION FOR URINARY RETENTIONJournal of Urology, 2005
- Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment responseBJU International, 2003
- Overactive bladder symptoms: Do we need urodynamics?Neurourology and Urodynamics, 2003
- Sacral Neuromodulation in Norway: Clinical Experience of the First Three YearsScandinavian Journal of Urology and Nephrology, 2002
- A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder complianceBJOG: An International Journal of Obstetrics & Gynaecology, 1997